

Management of adverse effects of Peg-IFN and ribavirin

Nature Reviews Gastroenterology and Hepatology
8, 212-223

DOI: [10.1038/nrgastro.2011.21](https://doi.org/10.1038/nrgastro.2011.21)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Regulation of cell growth by Notch signaling and its differential requirement in normal vs. tumor-forming stem cells in <i>Drosophila</i> . <i>Genes and Development</i> , 2011, 25, 2644-2658. | 2.7 | 68 |
| 2 | Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1080-1087. | 1.3 | 11 |
| 3 | Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521. | 1.5 | 13 |
| 4 | The role of viral and host genetics in natural history and treatment of chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 413-427. | 1.0 | 24 |
| 5 | Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study. <i>Clinical Therapeutics</i> , 2012, 34, 1883-1891. | 1.1 | 6 |
| 6 | Pegylated interferon- α induced hypoferrremia is associated with the immediate response to treatment in hepatitis C. <i>Hepatology</i> , 2012, 56, 492-500. | 3.6 | 48 |
| 7 | CpG and poly(I:C) stimulation of dendritic cells and fibroblasts limits herpes simplex virus type 1 infection in an IFN β -dependent and -independent way. <i>Antiviral Research</i> , 2012, 93, 39-47. | 1.9 | 20 |
| 8 | A new era in the treatment of chronic hepatitis C infection. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 71-79. | 0.7 | 4 |
| 9 | Safety of direct antiviral agents in real life. <i>Digestive and Liver Disease</i> , 2013, 45, S363-S366. | 0.4 | 14 |
| 10 | Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. <i>BMC Microbiology</i> , 2013, 13, 187. | 1.3 | 162 |
| 11 | All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naïve genotype 1 hepatitis C (NUCLEAR). <i>Journal of Viral Hepatitis</i> , 2013, 20, 699-707. | 1.0 | 25 |
| 12 | IFIT2 Is an Effector Protein of Type I IFN-Mediated Amplification of Lipopolysaccharide (LPS)-Induced TNF Secretion and LPS-Induced Endotoxin Shock. <i>Journal of Immunology</i> , 2013, 191, 3913-3921. | 0.4 | 48 |
| 13 | Autoimmune thyroid disorders in hepatitis C virus infection: Effect of interferon therapy. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 69. | 0.2 | 21 |
| 14 | Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877. | 13.9 | 992 |
| 15 | Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 18 Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4727-4735. | 1.4 | 22 |
| 16 | Improving access to treatment for patients with chronic hepatitis C through outreach. <i>Frontline Gastroenterology</i> , 2013, 4, 125-129. | 0.9 | 5 |
| 17 | Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Related Hepatitis. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 9-14. | 0.5 | 2 |
| 18 | Current and emerging antiviral treatments for hepatitis C infection. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 931-943. | 1.1 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The Association of Cytopenias and Weight Loss with Hepatitis C Virus Virologic Response in HIV/HCV-Coinfected Patients Treated with PEG-IFN and RBV. <i>Journal of the International Association of Providers of AIDS Care</i> , 2013, 12, 354-362. | 0.6 | 2 |
| 20 | Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. <i>Annals of Hepatology</i> , 2013, 12, 30-35. | 0.6 | 9 |
| 21 | Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients. <i>Seminars in Liver Disease</i> , 2014, 34, 072-078. | 1.8 | 6 |
| 22 | Management of acute and chronic HCV infection in persons with HIV coinfection. <i>Journal of Hepatology</i> , 2014, 61, S108-S119. | 1.8 | 19 |
| 23 | A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α . <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 56. | 1.0 | 8 |
| 24 | Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. <i>The Cochrane Library</i> , 2014, , CD005441. | 1.5 | 23 |
| 25 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. <i>Lancet, The</i> , 2014, 383, 515-523. | 6.3 | 522 |
| 26 | Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 416-423. | 1.0 | 11 |
| 27 | Interferons: Success in anti-viral immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 369-376. | 3.2 | 222 |
| 28 | Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5057-5071. | 2.9 | 96 |
| 29 | Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 145-151. | 1.1 | 10 |
| 30 | Impact of Hepatitis C Treatment Initiation on Adherence to Concomitant Medications. <i>Journal of the Association of Nurses in AIDS Care</i> , 2014, 25, 23-31. | 0.4 | 9 |
| 31 | HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1976-1994. | 2.9 | 28 |
| 35 | The role of HCV proteins on treatment outcomes. <i>Virology Journal</i> , 2015, 12, 217. | 1.4 | 23 |
| 36 | Randomized trial of low-dose peginterferon α -2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1. <i>Journal of Medical Virology</i> , 2015, 87, 2082-2089. | 2.5 | 0 |
| 37 | Hepatitis C in hemodialysis patients. <i>World Journal of Hepatology</i> , 2015, 7, 548. | 0.8 | 51 |
| 38 | The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment. <i>Comprehensive Psychiatry</i> , 2015, 60, 17-25. | 1.5 | 9 |
| 39 | Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 163-178. | 2.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 40 | Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. <i>Renal Failure</i> , 2015, 37, 1180-1184. | 0.8 | 2 |
| 41 | Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2016, 67, 272. | 0.2 | 4 |
| 42 | How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. <i>BMC Health Services Research</i> , 2016, 16, 247. | 0.9 | 5 |
| 43 | Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0166451. | 1.1 | 34 |
| 44 | Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). <i>Hepatology</i> , 2016, 63, 1430-1441. | 3.6 | 232 |
| 45 | A randomized, controlled study of peginterferon lambda-1a/ribavirin±daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365. | 1.2 | 8 |
| 46 | Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 478-485. | 0.7 | 20 |
| 47 | Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3108-3117. | 1.1 | 10 |
| 48 | Universal screening for chronic hepatitis C virus. <i>Liver International</i> , 2016, 36, 62-66. | 1.9 | 22 |
| 49 | Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 557-572. | 1.9 | 19 |
| 51 | Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. <i>Clinical Drug Investigation</i> , 2017, 37, 635-646. | 1.1 | 18 |
| 52 | Safety and efficacy of sofosbuvir±based direct-acting antiviral regimens for hepatitis C virus genotypes 1&4 and 6 in Myanmar: Real-world experience. <i>Journal of Viral Hepatitis</i> , 2017, 24, 927-935. | 1.0 | 31 |
| 53 | A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses. <i>MBio</i> , 2017, 8, . | 1.8 | 38 |
| 54 | Simeprevir with peginterferon ±2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. <i>BMC Infectious Diseases</i> , 2017, 17, 389. | 1.3 | 1 |
| 55 | A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (<i>S</i>)-1-((<i>R</i>)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-<i>N</i>-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 228-247. | | |
| 56 | mRNA-Seq reveals accumulation followed by reduction of small nuclear and nucleolar RNAs in yeast exposed to antiviral ribavirin. <i>FEMS Yeast Research</i> , 2017, 17, . | 1.1 | 1 |
| 57 | Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 348-353. | 0.5 | 4 |
| 58 | Simultaneous quantitative analysis of polyethylene glycol (PEG), PEGylated paclitaxel and paclitaxel in rats by MS/MSALL technique with hybrid quadrupole time-of-flight mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 145, 255-261. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 59 | Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA. <i>Journal of Medical Virology</i> , 2017, 89, 1033-1039. | 2.5 | 2 |
| 60 | CONTEXTUALIZAÇÃO E AVANÇOS NO TRATAMENTO DA HEPATITE C: UMA REVISÃO DA LITERATURA. <i>Visão Acadêmica</i> , 2017, 18, . | 0.1 | 3 |
| 61 | Add-on neurological benefits of antiviral therapy in HCV patients with chronic kidney disease – a nationwide cohort study. <i>BMC Gastroenterology</i> , 2017, 17, 99. | 0.8 | 3 |
| 62 | Revisão sistemática da eficácia e da segurança das terapias livres de interferon para hepatite C crônica em pacientes coinfectados com o Vírus da Imunodeficiência Humana. <i>Saúde Em Debate</i> , 2017, 41, 1212-1223. | 0.1 | 0 |
| 63 | Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. <i>Annals of Hepatology</i> , 2017, 16, 188-197. | 0.6 | 19 |
| 65 | Synthetic Approaches to New Drugs Approved During 2016. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7004-7031. | 2.9 | 58 |
| 66 | Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies. <i>Clinical Drug Investigation</i> , 2018, 38, 389-400. | 1.1 | 17 |
| 67 | Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 81-85. | 0.5 | 5 |
| 68 | Phytochemical profiling and antiviral activity of <i>Ajuga bracteosa</i> , <i>Ajuga parviflora</i> , <i>Berberis lycium</i> and Citrus lemon against Hepatitis C Virus. <i>Microbial Pathogenesis</i> , 2018, 118, 154-158. | 1.3 | 31 |
| 69 | Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2018, 90, 907-918. | 2.5 | 15 |
| 70 | Increased hope following successful treatment for hepatitis C infection. <i>Journal of Advanced Nursing</i> , 2018, 74, 724-733. | 1.5 | 3 |
| 71 | Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015. <i>Clinical Microbiology and Infection</i> , 2018, 24, 422-427. | 2.8 | 12 |
| 72 | Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 186-192. | 0.3 | 17 |
| 73 | Hepatitis C: evaluation of outcomes and georeferencing of cases in Santa Cruz do Sul, Brazil, between 2002 and 2015. A cross-sectional study. <i>Sao Paulo Medical Journal</i> , 2018, 136, 109-115. | 0.4 | 4 |
| 74 | HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 25-32. | 0.5 | 18 |
| 75 | Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 780-789. | 1.1 | 21 |
| 76 | The Role of Interferon for the Treatment of Chronic Hepatitis C Virus Infection. <i>Topics in Medicinal Chemistry</i> , 2019, , 97-113. | 0.4 | 5 |
| 77 | Benefits of hepatitis C cure with antivirals: why test and treat?. <i>Future Microbiology</i> , 2019, 14, 425-435. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 78 | A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 245-268. | 2.6 | 5 |
| 79 | Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets. <i>Gut</i> , 2020, 69, 158-167. | 6.1 | 31 |
| 80 | Risk factors associated with the severity of adverse drug reactions by Xiyanping injection: A propensity score-matched analysis. <i>Journal of Ethnopharmacology</i> , 2020, 250, 112424. | 2.0 | 19 |
| 81 | A comparative analysis of interferons and direct-acting antivirals on the expression of genes involved in hepatitis C pathogenesis. <i>Journal of Medical Virology</i> , 2020, 93, 6241-6246. | 2.5 | 1 |
| 82 | Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 592472. | 1.2 | 6 |
| 83 | Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. <i>Toxicology</i> , 2020, 435, 152422. | 2.0 | 19 |
| 84 | Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. <i>Pharmacotherapy</i> , 2020, 40, 416-437. | 1.2 | 166 |
| 85 | Recent progress of antiviral therapy for coronavirus disease 2019. <i>European Journal of Pharmacology</i> , 2021, 890, 173646. | 1.7 | 32 |
| 86 | Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 462-468. | 2.5 | 4 |
| 87 | On the possibility of eradicating hepatitis C in Russia. <i>Molekuliarnaia Genetika, Mikrobiologiya i Virusologiya</i> , 2021, 39, 31. | 0.1 | 1 |
| 88 | STING activation in alveolar macrophages and group 2 innate lymphoid cells suppresses IL-33-driven type 2 immunopathology. <i>JCI Insight</i> , 2021, 6, . | 2.3 | 17 |
| 89 | Gastrointestinal manifestations in COVID-19. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 1362-1388. | 0.7 | 76 |
| 90 | Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN- β . <i>Journal of Clinical Immunology</i> , 2021, 41, 1425-1442. | 2.0 | 39 |
| 91 | On the Possibility of Eradicating Hepatitis C in Russia. <i>Molecular Genetics, Microbiology and Virology</i> , 2021, 36, 27-38. | 0.0 | 0 |
| 92 | Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. <i>PLoS ONE</i> , 2016, 11, e0150655. | 1.1 | 15 |
| 93 | Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 1, 116-24. | 0.7 | 9 |
| 95 | Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 358. | 4.5 | 12 |
| 96 | Management of hepatitis C in patients with chronic kidney disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 408. | 1.4 | 33 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 97 | Protracted anaphylaxis developed after peginterferon α -2a administration for chronic hepatitis C. World Journal of Gastroenterology, 2015, 21, 2826. | 1.4 | 11 |
| 98 | Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World Journal of Gastroenterology, 2016, 22, 9613. | 1.4 | 8 |
| 99 | A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir. Health, 2016, 08, 780-786. | 0.1 | 6 |
| 100 | Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World Journal of Virology, 2012, 1, 174. | 1.3 | 28 |
| 101 | Interferon- α 2b induced anemia in severe coronavirus disease 2019 patients: a single centered, retrospective study. Immunopharmacology and Immunotoxicology, 2021, 43, 644-650. | 1.1 | 1 |
| 102 | A New Era in the Management of the Hepatitis C. International Journal of Clinical Medicine, 2014, 05, 660-666. | 0.1 | 1 |
| 103 | HEPATITIS C VIRUS AND HEPATITIS C-INFECTION. Brazilian Journal of Medicine and Human Health, 2015, 3, 19-28. | 0.0 | 0 |
| 104 | A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Research, 2016, 5, 2061. | 0.8 | 1 |
| 105 | Caracterización de pacientes con hepatitis C crónica tratados en un hospital de alta complejidad de Medellín. Revista Colombiana De Gastroenterología, 2019, 34, 249-260. | 0.1 | 0 |
| 106 | Hepatitis C Infection in Hemodialysis Patients. Current Health Sciences Journal, 2018, 44, 107-112. | 0.2 | 8 |
| 107 | Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. Gastroenterology and Hepatology, 2013, 9, 682-3. | 0.2 | 0 |
| 108 | Newer therapeutics for hepatitis C. Annals of Translational Medicine, 2016, 4, 31. | 0.7 | 0 |
| 109 | Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?. Viruses, 2022, 14, 96. | 1.5 | 9 |
| 110 | Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective. Molecules, 2022, 27, 1076. | 1.7 | 13 |
| 113 | O vírus da Hepatite C e a Hepatite C. , 2021, , 53-76. | | 0 |
| 114 | Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database. Haemophilia, 2023, 29, 186-192. | 1.0 | 4 |
| 115 | A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B. Canadian Liver Journal, 0, , . | 0.3 | 0 |
| 116 | Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus. Viruses, 2023, 15, 981. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 117 | Current Landscape of IFN-λ: Induction, Inhibition, and Potential Clinical Applications to Treat Respiratory Viral Infections. <i>ImmunoHorizons</i> , 2023, 7, 265-272. | 0.8 | 1 |